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Mitochondrial targeted antioxidants,
mitoquinone and SKQ1, not vitamin C,
mitigate doxorubicin-induced damage in
H9c2 myoblast: pretreatment vs.
co-treatment
Brian Sacks†, Halil Onal†, Rose Martorana, Amogh Sehgal, Amanda Harvey, Catherine Wastella, Hafsa Ahmad,
Erin Ross, Adona Pjetergjoka, Sachin Prasad, Robert Barsotti, Lindon H. Young and Qian Chen*
Abstract
Background: Preconditioning of the heart ameliorates doxorubicin (Dox)-induced cardiotoxicity. We tested whether
pretreating cardiomyocytes by mitochondrial-targeted antioxidants, mitoquinone (MitoQ) or SKQ1, would provide
better protection against Dox than co-treatment.
Methods: We investigated the dose-response relationship of MitoQ, SKQ1, and vitamin C on Dox-induced damage on
H9c2 cardiomyoblasts when drugs were given concurrently with Dox (e.g., co-treatment) or 24 h prior to Dox (e.g.,
pretreatment). Moreover, their effects on intracellular and mitochondrial oxidative stress were evaluated by 2,7-
dichlorofluorescin diacetate and MitoSOX, respectively.
Results: Dox (0.5–50 μM, n = 6) dose-dependently reduced cell viability. By contrast, co-treatment of MitoQ (0.05–
10 μM, n = 6) and SKQ1 (0.05–10 μM, n = 6), but not vitamin C (1–2000 μM, n = 3), significantly improved cell viability
only at intermediate doses (0.5–1 μM). MitoQ (1 μM) and SKQ1 (1 μM) significantly increased cell viability to 1.79 ± 0.12
and 1.59 ± 0.08 relative to Dox alone, respectively (both p < 0.05). Interestingly, when given as pretreatment, only
higher doses of MitoQ (2.5 μM, n = 9) and SKQ1 (5 μM, n = 7) showed maximal protection and improved cell viability to
2.19 ± 0.13 and 1.65 ± 0.07 relative to Dox alone, respectively (both p < 0.01), which was better than that of co-
treatment. Moreover, the protective effects were attributed to the significant reduction in Dox-induced intracellular and
mitochondrial oxidative stress.
Conclusion: The data suggest that MitoQ and SKQ1, but not vitamin C, mitigated DOX-induced damage. Moreover,
MitoQ pretreatment showed significantly higher cardioprotection than its co-treatment and SKQ1, which may be due
to its better antioxidant effects.
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Introduction
Doxorubicin (Dox) is a widely used anti-cancer drug due
to its ability to generate free radicals and interfere with
DNA replication on cancer cells. However, Dox also in-
duces severe cardiotoxicity, such as cardiomyopathy and
associated heart failure [1, 2]. Dexrazoxane is a drug
used to reduce Dox-induced cardiotoxicity possibly by
chelating iron and inhibiting Dox-topoisomerase II
(TOP II) interaction. On the other hand, dexrazoxane
can cause hematological toxicity, gastrointestinal dis-
comfort, and even increase the risk of developing a sec-
ond primary malignancy, which limit its use in women
with advanced or metastatic breast cancer [3, 4]. There-
fore, it is integral to identify new strategies to protect
the heart against Dox during chemotherapy.
Dox induces cardiac cell damage and/or apoptosis
through the same mechanisms as its ability to kill cancer
cells. It intercalates between DNA strands as well as in-
hibits the function of TOP II, leading to blockage of
DNA replication and transcription and breakage of DNA
double strand [3, 5]. This is somewhat selective for can-
cer cells because they are replicating more than most
normal cells. Dox also induces cardiotoxicity by accumu-
lating within the mitochondria and increasing reactive
oxygen species (ROS) production [6]. Dox can addition-
ally lead to a reduction in glutathione peroxidase and
catalase levels to decrease endogenous anti-oxidant cap-
acity [7]. Another feature is that Dox can interact with
cardiolipin to disrupt proper functioning of electron
transport chain in mitochondria [1, 2]. Because cardiac
tissue is most abundant in mitochondria compared to
other tissues, the heart is the most susceptible to Dox-
induced mitochondrial damage. Thus, protection of
mitochondria against Dox-induced oxidative stress
would be an effective strategy to mitigate cardiotoxicity
under Dox treatment.
Vitamin C is a representative common anti-oxidant,
which has been widely used, in daily life. Most studies
have shown vitamin C can protect the heart against Dox
by enhancing antioxidant and anti-inflammation effects
and reducing cellular damage and apoptosis in vitro and
in vivo studies [5, 8]. However, higher concentrations of
vitamin C have been suggested to be pro-oxidant which
can damage the cell [9]. Furthermore, vitamin C may
not specifically target the mitochondria when compared
to mitochondria-targeted antioxidants, such as mitoqui-
none (MitoQ) and 10-(6′-plastoquinonyl) decyltriphe-
nylphosphonium (SKQ1). MitoQ and SKQ1 are a
derivative of ubiquinone or plastoquinone conjugated to
decyl-triphenylphosphonium cation (TPP), respectively
[10, 11]. TPP is a lipophilic cation, and conjugation al-
lows the compound to concentrate in the mitochondria
with ease due to the powerful electrical gradient created
between the cationic TPP and drastic negative
membrane potential of the mitochondria (eg., − 160mV
to − 180 mV) [10]. Moreover, MitoQ is available over
counter for antioxidant supplement use and SKQ1
(Visomitin) is approved to treat dry eye conditions in
Russia [10]. It’s known that MitoQ reduces the produc-
tion of lipid peroxyl radicals and prevents lipid peroxida-
tion [12]. MitoQ is also demonstrated to reduce Dox-
induced damage in H9c2 cells and cardiomyopathy in
animal studies [13]. By contrast, SKQ1 has been found
to form a complex with cardiolipin in order to prevent
lipid peroxidation [14]. SKQ1 also shows a four-fold
higher decrease in peroxyl radicals than MitoQ in vitro
studies [11]. However, the effects of SKQ1 on Dox-
induced cardiotoxicity have not been well studied. Thus,
it is worthwhile to investigate if SKQ1 would provide the
same or better cardioprotection against Dox than vita-
min C or MitoQ. Since MitoQ and SKQ1 can also serve
as pro-oxidants at higher concentrations [15], it is im-
portant to understand their dose-response relationship
related to those effects. Recently, two labs have indicated
that preconditioning of cardiomyocytes by transient hyp-
oxia/reoxygenation or remote ischemic preconditioning
ameliorates Dox-induced cardiotoxicity and preserves
mitochondrial functions [16, 17]. Moreover, MitoQ pre-
treatment is found to upregulate antioxidant genes, at-
tenuate mitochondrial oxidative stress, and prevent
mitochondrial DNA depletion under intestinal ischemia/
reperfusion conditions [18]. However, there is lack of re-
search demonstrating the effects of mitochondria-
targeted antioxidants when given as pretreatment on
Dox-induced cardiac cell damage.
In this study, we first determined dose-dependent effects
of Dox on the cellular damage in H9c2 cells. We also
compared Dox’s effects to hydrogen peroxide (H2O2), a
common oxidative stress inducer. We then compared the
effects of vitamin C, MitoQ, or SKQ1 on Dox-induced cell
damage when drugs were given concurrently with Dox
(e.g., co-treatment) or 24 h prior to adding Dox (e.g., pre-
treatment). Lastly, we investigated the effects of Dox alone




Rat H9c2 cells (CRL-1446, American Type Culture Col-
lection (ATCC), Manassas, VA) were cultured in 75 cm2
flasks and petri dishes using 4.5 g/mL glucose DMEM
with 10% fetal bovine serum and 1% penicillin strepto-
mycin solution (Corning, Fisher Scientific, Waltham,
MA) at 37 °C and 5% CO2 in a humid incubator. Cell
media was changed every 2–3 days till cells reached 70–
80% confluence for passaging to prevent the loss of dif-
ferentiation potential according to the ATCC instruc-
tion. Meanwhile, some cells were harvested for
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experiments. Cell density after the collection was
counted using 0.3% trypan blue kit (Sigma-Aldrich, St.
Louis, MO) and plated 2 × 104 cells per well in a 96-well
plate. After seeding, H9c2 cells were incubated for 24 h
before treatments were administered. We used H9c2
cells within 5–20 passages for all the experiments be-
cause control cells showed similar morphology under
light microscopy (200X). Cell responses to all tested
compounds were very close across all the passages. All
the procedures for maintaining the cell line and con-
ducting experiments were carried out in a cell culture
hood with sterile techniques. Cells were checked for
contamination, morphology alteration, and confluence
by microscopy every day. When cells were contaminated
or deformed, all the flasks, media, and cell plates were
immediately discarded. The cell incubator was cleaned
and disinfected. Then, a new H9c2 cell line was freshly
restarted. All experiment groups included a non-treated
cell control to observe any physical, chemical, and
physiological changes among groups and cell passages.
To prevent chemical contamination, different treatments
were added to cells in separate columns on a cell plate.
Moreover, pipette tips were frequently changed during
procedures.
Experimental groups
Dox or H2O2 induced cell damage
Dox (0.5–50 μM; M.W. =579.98 g/mol, Sigma-Aldrich,
St. Louis, MO) or H2O2 (100–600 μM; M.W. =34.01 g/
mol, Sigma-Aldrich, St. Louis, MO) and solvent control
(e.g., medium) were applied to cells which were in 1-
day-old medium (e.g., after cell seeding for 24 h) to de-
termine cell damage. When cells were pretreated with
testing compounds, fresh medium was added after wash-
ing out the testing drugs. We have found that fresh
medium would reduce the cell damage induced by
H2O2. Therefore, Dox (0.1–50 μM) or H2O2 (100–
600 μM) and solvent control (e.g., medium) were applied
to cells with fresh medium to determine if there is any
different effects of Dox or H2O2 on cells with fresh
medium when compared to that with 1-day-old medium.
Cells were then incubated in Dox or H2O2 for 24 h be-
fore performing biochemical assays.
Vitamin C treatments
First, vitamin C (1–2000 μM; M.W. =276.12 g/mol,
Sigma-Aldrich, St. Louis, MO) was administered to cells
alone to determine if vitamin C itself caused any cell
damage. Then, vitamin C (1–2000 μM) was administered
with Dox (40 μM) as a co-treatment to evaluate if vita-
min C would exert any protection against Dox. Cells
were incubated for another 24 h before performing bio-
chemical assays.
MitoQ treatments
MitoQ (0.05–10 μM; M.W. =678.8 g/mol, Cayman
Chemical, Ann Arbor, Michigan) was applied to cells
alone to test if MitoQ itself caused any cell damage. Fur-
thermore, MitoQ was administered with Dox (40 μM) as
a co-treatment to evaluate if MitoQ would exert any
protection against Dox. We also used MitoQ as a pre-
treatment by adding MitoQ to cells for 24 h. Then
MitoQ was removed and cells were washed with PBS
twice, then fresh medium was added prior to administra-
tion of Dox (40 μM). Cells were incubated for another
24 h before performing biochemical assays.
SKQ1 treatments
Similarly as MitoQ, SKQ1 (0.05–10 μM; M.W. =617.6 g/
mol, Cayman Chemical, Ann Arbor, Michigan) was ap-
plied to cells alone to test if SKQ1 itself caused any cell
damage. Furthermore, SKQ1 was administered as a co-
treatment or pretreatment to determine if SKQ1 exerted
any cell protection against Dox (40 μM).
Biochemical assays
Cell viability analysis by cell counting kit-8 (CCK-8)
CCK-8 (Dojindo Molecular Technologies, Rockville,
MD) was used to evaluate cell viability based on intracel-
lular dehydrogenase activity. Tetrazolium salt is reduced
by dehydrogenases in live cells to form formazan, which
is soluble in tissue, and the amount of formazan dye
generated by dehydrogenases is directly proportional to
the number of living cells. After the corresponding treat-
ments described above, the medium was removed, and
cells were washed twice with PBS, then 100 μl fresh
medium was added. CCK reagent (10 μl) was added to
each well and cells were incubated for 4 h to allow the
reaction to complete. Absorbance was measured at 450
nm with ELISA plate reader, and the ratio of absorbance
in treated vs. non-treated (e.g., medium) control or Dox
alone was determined.
Cell viability by calcein assay
To further confirm cell damage caused by Dox or H2O2,
calcein assay was used to stain live cells. Calcein is a cell
permeable dye that is converted to green fluorescent cal-
cein after acetoxymethyl ester is hydrolyzed by intracel-
lular esterase in live cells. Calcein (Thermo Fisher
Scientific, Waltham, MA) was prepared using PBS. After
treatment of Dox or H2O2 for 24 h, culture media was
removed. Calcein solution (3 μM) was added to each
well and fluorescence intensity was measured at 485 nm/
535 nm with Fluoroskan Ascent CF after incubation for
30 min. The ratio of fluorescence intensity in treated vs.
non-treated (e.g., medium) control was determined.
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Intracellular ROS analysis by 2, 7-dichlorofluorescin
diacetate (DCFDA)
DCFDA (Thermo Fisher Scientific, Waltham, MA) is a
fluorogenic dye that allows quantification of hydroxyl,
peroxyl and other ROS activity within the cell. Cell per-
meable DCFDA is non- fluorescent compound which is
first deacylated by cellular esterase inside live cells, and
then oxidized by intracellular ROS to DCF, which is a
highly fluorescent compound that can be detected by
fluorescence spectrometry. First, H9c2 cells were loaded
with DCFDA after they were incubated with100 μl of
DCFDA (25 μM) for 45 min. Then, DCFDA reagent was
removed and 100 μl of DMEM medium was added to
each well. Thereafter, cells were treated with Dox (0.1–
50 μM) or Dox (40 μM) combined with MitoQ or SKQ1
to determine the effects of Dox alone or co-treatment of
drugs (MitoQ or SKQ1) on intracellular ROS. In another
set of experiments, DCFDA was added to cells after pre-
treatment of MitoQ or SKQ1 or vehicle for 24 h. After
removing DCFDA, cells were treated with Dox (40 μM)
to determine the effects of MitoQ or SKQ1 pretreatment
on Dox-induced intracellular ROS. Fluorescence inten-
sity was measured at 485 nm/535 nm by Fluoroskan As-
cent CF at 10 min and 24 h after cells were incubated
with Dox, The intracellular ROS levels were expressed
as the ratio between Dox to non-treated control or be-
tween pretreatment to Dox, respectively.
Mitochondrial superoxide (SO) analysis by MitoSOX
MitoSOX (Thermo Fisher Scientific, Waltham, MA) is a
novel fluorogenic dye used for detection of SO within the
mitochondria of live cells. The lipophilic, positively
charged TPP moiety within MitoSOX allows the dye to
concentrate within the mitochondrial matrix pending on
high mitochondrial membrane potential in live cells. The
dye is oxidized by SO to produce red fluorescence. First,
cells were treated by Dox (0.1–50 μM) alone, Dox (40 μM)
co-treated with MitoQ or SKQ1, or Dox (40 μM) follow-
ing pretreatment of MitoQ or SKQ1. After 24 h, the
medium was removed and cells were washed with PBS.
Thereafter, 100 μl MitoSOX (5 μM) reagent was added to
each well and incubated for 15min. Fluorescence intensity
was measured after changing the incubation solution to
medium at 531 nm/ 593 nm with Fluoroskan Ascent CF.
The mitochondrial SO levels were expressed as the ratio
between Dox to non-treated control or between pretreat-
ment to Dox, respectively.
Statistical analysis
All experiments were performed in triplicate and re-
peated at least three times. The data was expressed by
mean ± SE. The data were analyzed using ANOVA
followed by Student Newman Keuls and p value of <
0.05 was considered as statistical significance.
Results
Dox dose-dependently decreased cell viability similarly as
H2O2, but culture medium did not affect its cytotoxicity
The effects of Dox (0.5–50 μM) or H2O2 (100–600 μM)
on H9c2 cell viability under fresh and 1-day old medium
is shown in Fig. 1A-C. Compared to non-treated control
cells, treatment with Dox doses ranging from 5 μM to
50 μM significantly reduced cell viability (see Fig. 1A-B).
The reduction was dose-dependent. However, the dose-
response of Dox on cell viability was not significantly
different when Dox was directly added to 1-day-old
medium (n = 10) or fresh medium (n = 3). Dox (40 μM)
significantly reduced cell viability to 0.40 ± 0.03 or
0.37 ± 0.04 under old or fresh medium, respectively
(both p < 0.05 compared to non-treated control). Simi-
larly, H2O2 (100–600 μM) reduced cell viability in a
dose-dependent manner (see Fig. 1A and C). However,
the cytotoxicity induced by H2O2 (500 μM and 600 μM)
was significantly lower when H2O2 was added to 1-day-
old medium (n = 8) compared to those in fresh medium
(n = 6). After incubation of 600 μM H2O2 for 24 h, cell
viability relative to non-treated control in 1-day-old
medium (0.24 ± 0.08, n = 8, p < 0.01) was significantly
lower than in fresh medium (0.95 ± 0.10, n = 6).
We further confirmed the cell damage by Dox and
H2O2 in 1-day old medium by calcein staining (see
Fig. 2A-B). We found that cells after incubation of Dox
or H2O2 exhibited much less green staining when com-
pared to non-treated control (see Fig. 2A). Also, Dox
(n = 6) and H2O2 (n = 5) reduced cell viability in a dose-
dependent manner (see Fig. 2B), and the effects were
similar as those evaluated by CCK assay. Dox (40 μM)
and H2O2 (600 μM) significantly reduced cell viability to
0.49 ± 0.09 and 0.21 ± 0.02, respectively, when compared
to the non-treated control (both p < 0.01). In the follow-
ing experiments, Dox (40 μM) was used with antioxi-
dants to determine if vitamin C, SKQ1, or MitoQ would
protect cells against Dox-induced cell damage.
Antioxidants alone did not induce any cell damage
The effects of antioxidants alone on cell viability are illus-
trated in Fig. 3. All three antioxidants (n = 3–4) slightly in-
creased cell viability which was determined by measuring
live cell dehydrogenase activity. Moreover, higher dose
MitoQ (10 μM) showed a slight reduction in cell viability.
However, there was no significant difference when com-
pared to non-treated control or each other.
Mitochondrial targeted antioxidants, but not vitamin C,
protected H9c2 cells against Dox when given as co-
treatment
The effects of the different combinations of antioxidants
with 40 μM Dox on cell viability is shown in Fig. 4A-B.
Co-treatment of MitoQ or SKQ1 with Dox showed more
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live cells than those in Dox alone or vitamin C treatment
(see Fig. 4A). Also, we found that vitamin C (1–
2000 μM, n = 3) did not show any increase in cell viabil-
ity at any given dose. By contrast, SKQ1 (0.05–10 μM,
n = 6) and MitoQ (0.05–10 μM, n = 6) increased cell via-
bility in a dose-dependent manner (see Fig. 4A-B).
MitoQ showed slightly better protective effects than
SKQ1, but did not show any significant difference be-
tween them. MitoQ (1 μM) and SKQ1 (1 μM) signifi-
cantly increased cell viability to 1.79 ± 0.12 and 1.59 ±
0.08, respectively, when compared to Dox (both p <
0.05). Interestingly, we found the protective effects ex-
hibited by SKQ1 and MitoQ were either reduced or lost
when the doses were higher than 1 μM, respectively.
MitoQ and SKQ1 provided better protection against Dox
when given as pretreatment than co-treatment
The effects of pretreating cells by SKQ1 and MitoQ on
Dox-induced cell damage are shown in Fig. 5A-B. Pre-
treatment of MitoQ or SKQ1 showed more live cells
than those in Dox alone (see Fig. 4A). Moreover, we
found that SKQ1 (0.05–10 μM, n = 7) and MitoQ (0.05–
10 μM, n = 9) increased cell viability in a dose-dependent
manner. MitoQ (5 μM) and SKQ1 (5 μM) exerted the
maximal effect and showed a significant increase in cell
viability (2.03 ± 0.13 and 1.65 ± 0.07, respectively) when
compared to Dox (40 μM, both p < 0.05) (see Fig. 5B).
Furthermore, MitoQ showed significantly better protect-
ive effects than SKQ1 at 1 μM and 10 μM (see Fig. 5B).
Fig. 1 Effects of Dox or H2O2 on H9c2 cells when Dox or H2O2 were added to a fresh or 1-day-old medium. The representative pictures of cells
(100 X) after Dox or H2O2 incubation are shown in A (scale bar: 50 μm). Dose-dependent effects of Dox or H2O2 on cell viability are shown in B
and C, respectively. Unlike H2O2, the effects of Dox were not significantly different when Dox was applied to fresh vs old medium. **p < 0.01 vs
non-treated control; ##p < 0.01 vs fresh medium
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Fig. 2 Effects of Dox or H2O2 on H9c2 cell viability by a calcein staining assay when Dox or H2O2 were added to 1-day-old medium. The representative
pictures of stained cells (100 X) after Dox or H2O2 incubation are shown in A (scale bar: 50 μm). Dose-dependent effects of Dox or H2O2 on cell viability are
shown in B. Dox or H2O2 dose-dependently reduced cell viability. **p<0.01 vs non-treated control
Fig. 3 The effects of vitamin C, MitoQ, or SKQ1 on cell viability. There was no significant change in cell viability by all the three antioxidants
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Furthermore, we found that intermediate doses of
MitoQ (0.05–0.5 μM) exerted better protection when
given as co-treatment than pretreatment (see Fig. 6A-B).
By contrast, higher doses of MitoQ (1–10 μM) exerted
better protection when given as pretreatment (see
Fig. 6A). In particular, MitoQ (2.5 μM and 5 μM) pre-
treatment showed significantly higher cell viability
(2.19 ± 0.13 and 2.03 ± 0.13) than co-treatment (1.70 ±
0.17 and 1.33 ± 0.20, see Fig. 6). Similarly, SKQ1 also
showed better protection at intermediate doses (0.05–
1 μM) when given as co-treatment. However, higher
doses (5 μM and 10 μM) showed better effects when
given as pretreatment. No significant differences were
noticed among all the doses of SKQ1 between co-
treatment and pretreatment (Fig. 6B).
Dox significantly increased intracellular ROS and
Mitochondrial SO
A key mechanism of Dox-induced cardiotoxicity is oxi-
dative stress. The effects of Dox on intracellular ROS
and mitochondrial SO are shown in Fig. 7A-B. We
found that Dox (1–50 μM, n = 3) increased intracellular
ROS in a dose and time-dependent manner. We found
that the non-treated control only slightly increased
Fig. 4 The effects of vitamin C, MitoQ, or SKQ1 on cell viability against Dox when given as co-treatment. The representative pictures of cells (100
X) after co-treatment are shown in A (scale bar: 50 μm). The effects of different antioxidants on Dox-induced cell damage are illustrated in B.
MitoQ and SKQ1, but not vitamin C, significantly increased cell viability in the presence of Dox. *p < 0.05; **p < 0.01 vs Dox
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intracellular ROS (1.16 ± 0.06) at 24 h when compared to
its baseline. Dox (40 μM) significantly increased intracel-
lular ROS at 10 min to 1.61 ± 0.04 fold when compared
to the non-treated control baseline. At 24 h, Dox
(40 μM) significantly increased intracellular ROS to
4.87 ± 0.34 fold relative to the non-treated control base-
line (see Fig. 7A).
Similarly, Dox (1 μM - 50 μM, n = 4) increased mito-
chondrial SO in a dose-dependent manner. At 24 h, Dox
(40 μM) significantly increased mitochondrial SO to
5.37 ± 0.21 fold when compared to non-treated control
(see Fig. 7B).
MitoQ and SKQ1 reduced Dox-induced intracellular ROS
and mitochondrial SO
The effects of SKQ1 (0.05–5 μM, n = 4) and MitoQ
(0.05–5 μM, n = 4) co-treatment or pretreatment on
Dox-induced intracellular ROS levels at 24 h are
Fig. 5 The effects of pretreatment of MitoQ or SKQ1 on Dox-induced cell viability reduction. The representative pictures of cells (100 X) after
pretreatment are shown in A (scale bar: 50 μm). The effects of MitoQ and SKQ1 pretreatment on Dox-induced cell damage are illustrated in B.
Higher doses of MitoQ or SKQ1 significantly improved cell viability when given as pretreatment. Moreover, MitoQ exerted significantly higher
protection than SKQ1. *p < 0.05; **p < 0.01 vs Dox; ##p < 0.01 vs SKQ1
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illustrated in Fig. 8A-D. We found co-treatment or pre-
treatment of SKQ1 (0.05–5 μM, n = 4) and MitoQ (0.05–
5 μM, n = 4) significantly reduced Dox-induced intracel-
lular ROS levels in a dose-dependent manner (all p <
0.05). When given as co-treatment, intermediate dose
(1 μM) of SKQ1 and MitoQ showed maximal reduction
of intracellular ROS levels to 0.63 ± 0.03 and 0.54 ± 0.02,
respectively, when compared to Dox alone (see Fig. 8A).
By contrast, when given as pretreatment, higher dose
(5 μM) of SKQ1 and MitoQ showed higher reduction of
intracellular ROS levels to 0.60 ± 0.03 and 0.43 ± 0.01, re-
spectively, when compared to Dox alone (see Fig. 8B).
Both were significantly higher than the corresponding
effects of 5 μM of SKQ1 and MitoQ when administered
as co-treatment (both p < 0.05, see Fig. 8C-D). Moreover,
only 0.5 μM MitoQ co-treatment exhibited a
significantly higher reduction in intracellular ROS levels
when compared to 0.5 μM SKQ1 (p < 0.05, see Fig. 8A).
By contrast, most doses (0.05, 0.5–5 μM) of MitoQ pre-
treatment exhibited a significantly higher reduction in
intracellular ROS levels than SKQ1 pretreatment (all p <
0.05, see Fig. 8B).
The effects of SKQ1 (0.05–5 μM, n = 3) and MitoQ
(0.05–5 μM, n = 3–4) co-treatment or pretreatment on
Dox-induced mitochondrial SO at 24 h are illustrated in
Fig. 9A-D. Similarly, co-treatment or pretreatment of
SKQ1 and MitoQ significantly reduced mitochondrial
SO, although only pretreatment showed a dose-
dependent manner (see Fig. 9A-B). Moreover, co-
treatment of SKQ1 and MitoQ showed better reduction
on mitochondrial SO levels at lower dose range (0.05–
1 μM), whereas pretreatment of both drugs showed
Fig. 6 The comparison between pretreatment and co-treatment of MitoQ (A) and SKQ1 (B) on Dox-induced cell damage. Pretreatment and co-
treatment of MitoQ and SKQ1 significantly protected cells against Dox by demonstrating higher cell viability. Moreover, pretreatment of MitoQ,
not SKQ1, exerted significantly higher protection than co-treatment at higher doses. *p < 0.05; **p < 0.01 vs Dox; ##p < 0.01 vs MitoQ co-treatment
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better effects at higher dose range (1–5 μM). Co-
treatment of MitoQ (5 μM) and SKQ1 (5 μM) slightly re-
duced mitochondrial SO to 0.82 ± 0.04 and 0.82 ± 0.16,
respectively, when compared to Dox alone. By contrast,
pretreatment of MitoQ (5 μM) and SKQ1 (5 μM) signifi-
cantly reduced mitochondrial SO to 0.43 ± 0.04 and
0.43 ± 0.05, respectively, when compared to Dox alone
(both p < 0.01). Both were also significantly higher than
the corresponding effects of 5 μM of SKQ1 and MitoQ
when administered as co-treatment (both p < 0.05, see
Fig. 9C-D). Although MitoQ exhibited better reductions
in mitochondrial SO at most doses than SKQ1 when
given as co-treatment or pretreatment, there were no
significant differences.
Discussion
In summary, we found that Dox (0.5–50 μM) dose-
dependently reduced H9c2 cell viability. The effects were
similar as those caused by a common oxidative stress in-
ducer, H2O2. However, unlike H2O2, there was no differ-
ence in Dox cytotoxicity when Dox was added to a fresh
medium or 1-day-old medium. Thereafter, we showed
that mitochondrial targeted antioxidants, SKQ1or MitoQ,
but not the common antioxidant, vitamin C, significantly
mitigated Dox-induced cell damage when given as co-
treatment or pretreatment. Interestingly, pretreatment of
MitoQ provided significantly higher efficacy of cell protec-
tion when compared to MitoQ co- treatment or SKQ1
pretreatment. Lastly, we demonstrated that Dox dose-
Fig. 7 The effects of Dox on intracellular ROS (A) and mitochondrial SO (B) levels. Dox showed dose-dependent increase in intracellular ROS and
mitochondrial SO levels. **P < 0.01 vs the non-treated control
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dependently increased intracellular ROS and mitochon-
drial SO. By contrast, co-treatment or pretreatment of
SKQ1 or MitoQ significantly reduced Dox-induced intra-
cellular ROS and mitochondrial SO. However, pretreat-
ment shower higher reduction only at higher doses than
co-treatment.
Dox induced H9c2 cell damage by increasing intracellular
and mitochondrial ROS
Dox is a powerful chemotherapeutic drug and widely
used in solid cancer treatment [19]. Dox usage is limited
due to induction of irreversible cardiotoxicity [1, 20].
This damage is characterized by cardiac cell apoptosis or
necrosis which can lead to cardiomyopathy [21]. Our
study showed that Dox (0.5–50 μM) dose-dependently
decreased H9c2 myoblast cell viability after incubation
for 24 h. The cell viability was evaluated by measuring
intracellular dehydrogenase activity of viable cells and
confirmed by calcein staining. Our results are consistent
with a study by Zhang et al. showing that Dox induced
cell damage in a dose- and time-dependent manner. Dox
(5 μM) caused about 30% reduction in H9c2 cell viability
after incubation for 24 h [20], which is similar to our
data. By contrast, Dallons et al. showed Dox (1–50 μM)
had no effect on cell viability after incubation for 4 h,
whereas Dox (1 μM) showed 60% reduction in cell via-
bility after 24 h treatment when cell viability was mea-
sured by crystal violet assay [21]. The difference of Dox
induced cell damage is possibly due to the sensitivity of
methodology used to evaluate cell viability. Moreover,
Dallons seeded cells at 3 × 104 cells/cm2 and experi-
ments started after cell seeding for 48 h. By contrast, we
seeded cells at 6 × 104 cells/cm2 and experiments started
after cell seeding for 24 h. Researchers have found that
cell numbers can influence cell damage effects induced
by oxidizer [22].
In this study, we also showed that cell damage induced
by H2O2 could be significantly impacted by fresh
medium when compared to 1-day-old medium. The dif-
ference may be due to antioxidant effects provided by
fetal bovine serum and α-keto acid in fresh medium
[23]. However, we did not see any significant difference
Fig. 8 Effects of co-treatment or pretreatment of SKQ1 or MitoQ on Dox-induced increase in intracellular ROS levels. Co-treatment (A) and pretreatment (B) of
SKQ1 and MitoQ significantly attenuated Dox-induced increase in intracellular ROS levels when compared to Dox alone. Pretreatment (C-D) showed better
reduction in intracellular ROS levels than co-treatment only at a higher dose (5μM). Moreover, MitoQ exerted a significantly higher reduction in intracellular ROS
levels than SKQ1. **p<0.01 vs Dox; #p<0.05, ##p<0.01 vs MitoQ or SKQ1, respectively
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in cell viability by Dox between fresh medium and 1-
day-old medium. Therefore, we could add Dox into the
fresh medium after washing out MitQ or SKQ1 after
both drugs were given as pretreatment.
Oxidative stress is a major mechanism mediating Dox-
induced cardiac damage. It has been found that Dox, a
cationic compound, can accumulate in mitochondria
100 times more than in the cytosol due to larger mito-
chondrial membrane potential (e.g., − 160 to -180 mV).
Moreover, Dox interacts with cardiolipin forming elec-
trostatic bonds and disrupting the mitochondrial elec-
tron transport chain, particularly complex I and II [24].
In consequence, the dysfunctional electron transport
chain facilitates SO generation and overwhelms the
mitochondrial antioxidant capacity in the heart. Mean-
while, Dox itself undergoes redox cycling and directly re-
duces to a semiquinone species through interaction with
complex I. This reduced semiquinone version of Dox
can oxidize oxygen and form SO. Additionally, Dox can
regulate mitochondrial NADPH oxidase increasing ROS
production [25]. In this study, we found that Dox in-
creased intracellular ROS in a dose and time-dependent
manner. Intracellular ROS measured by DCF fluores-
cence intensity started to increase after Dox incubation
for 10 min and it continued to rise until 24 h. Moreover,
we specifically measured mitochondrial SO levels by
MitoSOX after Dox incubation for 24 h. We found that
the dose-response of Dox-induced mitochondrial SO in-
crease was very similar as the dose-response of Dox-
induced intracellular ROS increase at 24 h. The data is
consistent with Kuznetsov et al. showing Dox increased
intracellular ROS evaluated by measuring DCF fluores-
cence intensity paralleled with mitochondrial redox state
and membrane potential [26]. Asensio-Lopez et al. also
showed that Dox dose and time-dependently increased
intracellular ROS. Moreover, by utilizing MitoTracker
green to locate mitochondria, they found that Dox
started to appear in mitochondria at 15 min after admin-
istration. It was accompanied with increased ROS fluor-
escence at mitochondria as well. Both intensities
Fig. 9 Effects of co-treatment or pretreatment of SKQ1 or MitoQ on Dox-induced increase in mitochondrial SO levels. Co-treatment (A) or pretreatment (B) of
SKQ1 and MitoQ significantly attenuated Dox-induced mitochondrial SO levels. Pretreatment (C-D) showed better reduction in mitochondrial SO levels than co-
treatment only at a higher dose (1–5μM). Moreover, MitoQ exerted better reduction than SKQ1 at most doses. **p<0.01 vs Dox; #p<0.05, ##p<0.01 vs MitoQ
or SKQ1, respectively
Sacks et al. BMC Pharmacology and Toxicology           (2021) 22:49 Page 12 of 16
increased as a function of time [25]. In consequence, in-
creased ROS levels in mitochondria lead to membrane
potential collapse, ATP production decrease, lipid perox-
idation, cytochrome C release and mitochondrial DNA
damage [1, 20]. A large amount studies have confirmed
that Dox induces apoptosis in cardiomyocytes by in-
creasing cytochrome C and caspase 3 and 9 activity [1,
20, 21].
Vitamin C failed to protect cells against Dox-induced
damage
Because oxidative stress is a major and early event after
giving Dox, there are numerous researchers investigating
if antioxidants can protect the heart against Dox-
induced cardiotoxicity. Most preclinical studies found
that common antioxidants, such as vitamin C, can pro-
tect the heart against Dox. Viswanatha Swamy et al.
showed that vitamin C (20 mg/kg orally) when given 15
days before or 15 days after Dox significantly reduced
heart cell damage and oxidative stress by enhancing
antioxidant enzymes (e.g., superoxide dismutase, cata-
lase) in rats [27]. Similarly, Akolkar et al. demonstrated
better cardiac structure and function in rats when vita-
min C (50 mg/kg, orally) was given a week before and
continued till 2 weeks after Dox injection. Moreover,
they illustrated vitamin C significantly mitigated Dox-
induced nitrosative stress, proapoptotic proteins (e.g.,
caspase 3), inflammatory cytokines (e.g., interleukin 6),
and the relevant signaling proteins (e.g., p53, nuclear
factor kappa light chain enhancer of activated B cells,
autophagy) in rats and isolated cardiomyocytes [5, 8, 28].
However, it is still a lack of sufficient clinical research
evidence to prove the effectiveness of vitamin C in the
attenuation of cardiotoxicity caused by Dox [29, 30].
In this study, we expected that vitamin C would miti-
gate Dox-induced cell damage. Moreover, it could serve
as an effective control to compare mitochondrial-
targeted antioxidants’ effects. We first found that vita-
min C (1–2000 μM) alone only slightly increased cell
viability after incubation for 24 h. However, when vita-
min C (1–2000 μM) was applied concurrently with Dox,
vitamin C failed to show any protective effects. More-
over, higher doses of vitamin C (1000 μM and 2000 μM)
showed slightly lower cell viability than Dox alone. So
far, vitamin C has not shown any protection against
Dox-induced cardiotoxicity in clinical studies [29, 30].
This may be because vitamin C is not able to reach
sources of ROS (e.g. mitochondria) quickly enough to
scavenge ROS or its potential pro-oxidant property.
Vitamin C is hydrophilic and it gets into the cell or cel-
lular organelles by Na-dependent vitamin C transporter
or glucose transporter. AKolkar et al. showed that Dox
downregulated the expression of both transporter pro-
teins in the cardiomyocytes [8]. Moreover, the
distributions of vitamin C in different intracellular com-
partments vary in different tissues. For example, vitamin
C concentration is five times less in the mitochondria of
mouse skeletal muscle than that in the liver [31]. Fur-
thermore, studies indicate that vitamin C can become
pro-oxidant at higher concentration (e.g., > 1000 μM),
higher intracellular transition metal ions, or dysfunc-
tional mitochondria [32–34]. In addition, a higher Dox
concentration (e.g., 40 μM) was used in this study than
other studies (e.g., 10 μM). All the above factors may
contribute to why vitamin C showed no cell protection
against Dox in this study.
MitoQ and SKQ1, given as pretreatment, mitigated Dox-
induced cell damage at higher degree than co-treatment
Due to Dox mainly accumulating in the mitochondria to
induce oxidative stress, mitochondrial-targeted antioxi-
dants would be more efficient to mitigate Dox-induced
cell damage. MitoQ and SKQ1 are two well-studied
mitochondrial-targeted antioxidants [35]. They are ubi-
quinone and plastoquinone, respectively, conjugated to a
TPP, a lipophilic cation. The conjugated drugs accumu-
late several hundred times more in the mitochondria
than cytosol due to larger membrane potential within
the cell [10, 36]. Inside mitochondria, MitoQ and SKQ1
switch between their reduced and oxidized form via the
electron transport chain, with the reduced form able to
scavenge ROS [15, 37]. However, MitoQ and SKQ1 can
be pro-oxidants at higher doses [15]. We found that
MitoQ (0.05–5 μM) and SKQ1 (0.05–10 μM) alone
slightly increased cell viability when compared to non-
treated control. By contrast, a higher dose of MitoQ
(10 μM) slightly reduced H9c2 cell viability by 5%. Men-
dez et al. also showed that MitoQ (10 μM) is cytotoxic
to platelets [38].
It is well-known that heart preconditioning by transi-
ent ischemia/reperfusion episodes allows the heart de-
velop resilience to endure a harsher insult, such as
prolonged ischemia/reperfusion injury [39]. Currently,
this strategy has been tried to mitigate Dox-induced car-
diotoxicity. Maulik et al. showed that simulated precon-
ditioning by hypoxia/reoxygenation attenuated Dox-
induced cell damage in primary adult cardiac myocytes.
However, a ROS scavenger, N-acetyl cysteine, failed to
show any protection when given concurrently with Dox
[16]. Similarly, Galan-Arriola et al. found that remote is-
chemia preconditioning before intracoronary injection of
Dox preserved significantly better left ventricular ejec-
tion fraction, mitochondrial morphology, and DNA cop-
ies in pigs’ heart [17]. Instead of using ischemic
preconditioning, we pretreated cells with mitochondrial
targeted antioxidants, MitoQ or SKQ1, 24 h prior to
Dox in this study. We also compared the effects of pre-
treatment to those of co-treatment. We found both co-
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treatment and pretreatment mitigated Dox-induced cell
damage in H9c2 myoblast cells. However, the dose-
responses were different between co-treatment and pre-
treatment. Co-treatment showed significant protection
at intermediate doses of MitoQ (0.5–1 μM) and SKQ1
(1 μM); whereas higher doses showed reduced protec-
tion. By contrast, when given as pretreatment, higher
doses of MitoQ (1–10 μM) and SKQ1 (5 μM) were re-
quired to protect the cells against Dox. Moreover, the ef-
ficacy of protection by MitoQ pretreatment was
significantly better than its co-treatment. We further
found that the protection may be related to the dose-
dependent reduction in intracellular ROS and mitochon-
drial SO. It is noticeable that both drug’s antioxidant ef-
fects shared the similar shift of dose-dependent response
between co-treatment and pretreatment. To our know-
ledge, the present study showed that pretreatment of
mitochondrial-targeted antioxidants has higher efficacy
against Dox-induced cell damage than co-treatment for
the first time. The difference possibly is due to the fol-
lowing reasons: 1. Accumulation of MitoQ or SKQ1 in
mitochondria depends on mitochondrial membrane po-
tential [10]. When the drugs were co-administered with
Dox, Dox dissipated the mitochondrial membrane po-
tential which possibly reduced the drug accumulation in
mitochondria; 2. It has been reported that higher doses
of MitoQ and SKQ1 can be prooxidants. In particular,
MitoQ shows higher pro-oxidant property at lower
doses than SKQ1 in vitro studies [13]. Moreover, Huang
et al. found that MitoQ (10 μM) reduced mitochondrial
membrane potential in pancreatic acinar cells [40]. We
found that higher doses of SKQ1 or MitoQ (e.g. 5 and
10 μM) when given as co-treatment showed less cell pro-
tection or no protection at all. 3. MitoQ/SKQ1 and Dox
exert effects via the electron transport chain and cardio-
lipin, which may lead to interference when given at the
same time. For example, Dox needs to be converted to
semiquinone causing ROS increase by complex I. By
contrast, MitoQ relies on complex I and II to recycle be-
tween the reduced and oxidized forms [41]. Similarly,
SKQ1 recharges itself between reduced and oxidized
forms via complex II and complex III [37]. Furthermore,
Dox and SKQ1 showed higher affinity for mitochondrial
cardiolipin than MitoQ. However, Dox binding disrupts
cardiolipin whereas SKQ1or MitoQ protects cardiolipin
from oxidation to preserve mitochondria’s normal func-
tion [24, 42]. By contrast, when MitoQ or SKQ1 was ap-
plied before Dox, drug accumulation into mitochondria
and the antioxidant capacity was unlikely influenced. All
the above presumptions warrant further investigation to
support that pretreatment would be a better strategy
when giving mitochondrial-targeted antioxidants.
Additionally, we demonstrated that MitoQ exhibited
significantly higher efficacy against Dox than SKQ1
when both were given as pretreatment. The cellular pro-
tection may be partially related to its higher reduction
on intracellular ROS and mitochondrial SO than SKQ1
as our data suggested. Plenty of studies support the con-
cept that MitoQ can mitigate Dox-induced cardiotoxi-
city by reducing oxidative stress [1, 13]. By contrast,
SKQ1 has not been widely studied in Dox-induced car-
diotoxicity. However, it has been used in eye drops as a
defense against oxidative stress due to dry eye syndrome
[43]. SKQ1 has been also studied to promote survival of
kidney epithelial cells and significantly improved survival
of rats subjected to ischemia/reperfusion injury by redu-
cing oxidative stress [44]. In vitro studies suggest that
SKQ1 has antioxidant effects at lower concentrations
than MitoQ [13]. Moreover, the reduced form of SKQ1
has a four-fold higher decrease in peroxyl radicals than
the reduced form of MitoQ [11]. In addition to their
antioxidant ability, Hu et al. recently indicated that
MitoQ pretreatment activated Nrf2 signaling to enhance
antioxidant capacity and to protect mitochondrial DNA
in an intestinal ischemia/reperfusion model [18]. The
role of Nrf2 signaling in cardioprotection provided by
pretreatment of MitoQ or SKQ1 needs to be further
elucidated.
Limitation
We acknowledge that this study was performed on a rat
H9c2 cardiomyoblast cell line instead of primary cul-
tured cardiomyocytes. However, Kuznetsov et al. com-
pared H9c2 cells’ mitochondrial biogenesis, function and
response to hypoxia/reoxygenation to primary cardio-
myocytes’. They suggested that H9c2 cells were very
similar to primary heart cells regarding the energy me-
tabolism and mitochondrial properties [45]. Therefore,
we would like to further validate the effects of pretreat-
ment of mitochondrial-targeted antioxidants in a Dox-
induced cardiotoxicity animal model. Moreover, we did
not evaluate whether Dox’s anti-cancer effects would be
compromised by using mitochondrial-targeted antioxi-
dants as co-treatment or pretreatment. Rao et al. dem-
onstrated that MitoQ exerted 30 times more cytotoxicity
to breast cancer cell lines than to healthy mammary epi-
thelial cells [46]. Moreover, they also found that MitoQ
not only increased Dox’s anti-cancer effects but also mit-
igated Dox-induced cardiotoxicity [47]. Similarly, SKQ1
also showed to attenuate cell growth in fibrosarcoma
and rhabdomyosarcoma tumor cell lines and related ani-
mal models [48]. However, given the possibility of com-
petition when mitochondrial-targeted antioxidants are
co-treated with Dox, it will be very intriguing to find out
if administration of MitoQ or SKQ1 as pretreatment
prior to Dox would provide better anti-cancer effects
than co-treatment. It will also shine some light on how
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cancer patients can safely take antioxidants and not
interfere with anti-cancer treatments’ benefits.
Conclusion
This present study showed that Dox dose-dependently
reduced cell viability of H9c2 cells by increasing intracel-
lular ROS and mitochondrial SO. Mitochondrial targeted
antioxidants, MitoQ and SKQl, but not vitamin C, sig-
nificantly mitigated Dox-induced cell damage when
given as co-treatment or pretreatment. Interestingly,
MitoQ pretreatment showed significantly higher efficacy
in cellular protection than MitoQ co-treatment and
SKQ1 pretreatment. The protective effects by MitoQ
and SKQ1 were associated with significant reduction in
intracellular ROS and mitochondrial SO. The data also
demonstrate that pretreating cardiomyocytes by MitoQ
prior to Dox may exert significantly better cardioprotec-
tion than co-treatment. The mechanisms underlying the
difference between co-treatment and pretreatment
against Dox-induced cardiac cell damage and the im-
pacts on Dox’s anti-cancer effects will be explored in fu-
ture studies.
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